摘要
目的探讨人β-防御素-2(hBD-2)在肺癌组织中的表达及其临床意义。方法收集32例不同类型肺癌的标本,每份标本取癌组织及癌旁正常组织。采用免疫组化及Western blot检测其hBD-2的表达,并作半定量分析。结果hBD-2在癌组织中的表达高于正常组织,其表达在不同的临床分期之间存在显著性差异,而在不同病理类型的癌症组织中的表达差异无统计学意义。同样,免疫组化显示hBD-2在肺癌组织表达较正常组织高。结论人β-防御素-2可能参与肺癌的发病机制,其表达水平可能与肺癌病情进展有关。
Objective To study human beta-defensin-2（hBD-2） expression and clinical correlation on lung carcinoma. Methods 32 carcinoma specimens come from carcinoma tissue, as well as matched specimens from pan cancerous normal tissue of human lung. The expression of hBD-2 was detected and analyzed semiquantitatively by Western blot and immnohistochemistry. Results hBD-2 expression in lung carcinoma was significantly higher than that in normal lung tissue. There was a significant difference in different clinical stage of lung carcinoma. But the expression of hBD-2 was no significant difference in different type of lung cancer. Meanwhile, immnohistochemistry suggested that the expression of hBD-2 was higher in lung carcinoma than that in normal lung tissue. Conclusion The amount of hBD-2 expression was correlated with development of lung carcinoma and it possibly took part in the pathogenesy in lung carcinoma.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2008年第2期110-112,共3页
Cancer Research on Prevention and Treatment
